What is the share price of Sanjivani Paranteral Ltd (SANJIVIN) today?
The share price of SANJIVIN as on 11th July 2025 is ₹211.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanjivani Paranteral Ltd (SANJIVIN) share?
The past returns of Sanjivani Paranteral Ltd (SANJIVIN) share are- Past 1 week: -0.32%
- Past 1 month: -10.20%
- Past 3 months: -2.17%
- Past 6 months: -36.71%
- Past 1 year: 5.46%
- Past 3 years: 347.23%
- Past 5 years: 2452.63%
What are the peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN)?
The peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN) include:What is the dividend yield % of Sanjivani Paranteral Ltd (SANJIVIN) share?
The current dividend yield of Sanjivani Paranteral Ltd (SANJIVIN) is 0.22.What is the market cap of Sanjivani Paranteral Ltd (SANJIVIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd (SANJIVIN) is ₹266.36 Cr as of 11th July 2025.What is the 52 week high and low of Sanjivani Paranteral Ltd (SANJIVIN) share?
The 52-week high of Sanjivani Paranteral Ltd (SANJIVIN) is ₹396.95 and the 52-week low is ₹190.What is the PE and PB ratio of Sanjivani Paranteral Ltd (SANJIVIN) stock?
The P/E (price-to-earnings) ratio of Sanjivani Paranteral Ltd (SANJIVIN) is 32.92. The P/B (price-to-book) ratio is 9.55.Which sector does Sanjivani Paranteral Ltd (SANJIVIN) belong to?
Sanjivani Paranteral Ltd (SANJIVIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanjivani Paranteral Ltd (SANJIVIN) shares?
You can directly buy Sanjivani Paranteral Ltd (SANJIVIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanjivani Paranteral Ltd
SANJIVIN Share Price
211.203.23% (-7.05)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANJIVIN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANJIVIN Performance & Key Metrics
SANJIVIN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 32.88 | 9.55 | 0.22% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
SANJIVIN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SANJIVIN Company Profile
Sanjivani Paranteral is engaged in the business of pharmaceutical products.
SUNPHARMA
PE Ratio
36.50
36.50
1Y Return
4.00%
4.00%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.64
22.64
1Y Return
2.34%
2.34%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.13
59.13
1Y Return
13.13%
13.13%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
18.58
18.58
1Y Return
4.24%
4.24%
Buy Reco %
51.72
51.72
MANKIND
PE Ratio
52.73
52.73
1Y Return
18.31%
18.31%
Buy Reco %
81.25
81.25
SANJIVIN Sentiment Analysis
SANJIVIN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANJIVIN Stock Summary · May 2025
Sanjivani Parenteral Limited demonstrated robust financial performance in Q4 and FY '25, with a remarkable 41.3% year-on-year revenue growth, driven by new product launches and strategic market expansions, particularly in French-speaking African nations and Central and Latin America. The company is enhancing its operational readiness through joint ventures, notably in Prague, which positions it favorably in the European nutraceutical market. Despite challenges such as increased employee costs and initial production ramp-up at new facilities, management remains optimistic about future growth, supported by stable raw material prices and a focus on local manufacturing. The commitment to operational efficiency and a diverse product portfolio is expected to sustain momentum as the company navigates new market entries and regulatory landscapes.
SANJIVIN Stock Growth Drivers
SANJIVIN Stock Growth Drivers
7Strong Financial Performance
Sanjivani Parenteral Limited reported significant revenue growth, achieving a 41.3% year-on-year increase in Q4 FY
Expansion of Product Portfolio
The company successfully expanded its product portfolio to 160 products by launching 15 new products
SANJIVIN Stock Challenges
SANJIVIN Stock Challenges
0
Hmm, looks like there are nochallenges
SANJIVIN Forecast
SANJIVIN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SANJIVIN
SANJIVIN
Income
Balance Sheet
Cash Flow
Annual Normal View
SANJIVIN Income Statement
SANJIVIN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 35.52 | 18.45 | 26.05 | 16.61 | 25.36 | 30.85 | 42.02 | 59.47 | 71.31 | 71.31 | ||||||||||
Raw Materials | 28.67 | 24.94 | 14.60 | 9.93 | 14.14 | 12.66 | 19.84 | 34.37 | 59.75 | 59.75 | ||||||||||
| Power & Fuel Cost | 0.96 | 1.08 | 0.73 | 0.58 | 0.78 | 0.98 | 1.10 | 1.14 | ||||||||||||
| Employee Cost | 2.77 | 2.96 | 2.37 | 2.25 | 2.13 | 2.73 | 2.91 | 3.74 | ||||||||||||
| Selling & Administrative Expenses | 5.09 | 3.11 | 2.76 | 2.60 | 2.91 | 7.22 | 5.32 | 9.45 | ||||||||||||
| Operating & Other expenses | 18.45 | 38.09 | 6.39 | 1.33 | 3.01 | 1.30 | 6.66 | 2.01 | ||||||||||||
EBITDA | -20.42 | -51.73 | -0.80 | -0.08 | 2.39 | 5.96 | 6.19 | 8.76 | 11.56 | 11.56 | ||||||||||
| Depreciation/Amortization | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.62 | 0.62 | ||||||||||
| PBIT | -21.62 | -52.92 | -1.97 | -1.15 | 1.53 | 5.08 | 5.30 | 7.83 | 10.94 | 10.94 | ||||||||||
| Interest & Other Items | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.59 | 0.59 | ||||||||||
| PBT | -26.41 | -53.37 | -2.30 | -1.81 | 1.40 | 4.87 | 4.94 | 7.58 | 10.35 | 10.35 | ||||||||||
| Taxes & Other Items | -0.19 | -0.32 | -0.23 | -0.10 | -0.01 | 0.03 | 0.43 | 1.41 | 2.26 | 2.25 | ||||||||||
| Net Income | -26.22 | -53.05 | -2.07 | -1.71 | 1.41 | 4.84 | 4.51 | 6.17 | 8.09 | 8.10 | ||||||||||
| EPS | -44.45 | -89.94 | -3.51 | -2.90 | 1.96 | 5.23 | 4.51 | 5.69 | 6.89 | 6.93 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
SANJIVIN Company Updates
SANJIVIN Stock Peers
SANJIVIN Past Performance & Peer Comparison
SANJIVIN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanjivani Paranteral Ltd | 32.92 | 9.55 | 0.22% |
| Sun Pharmaceutical Industries Ltd | 36.50 | 5.50 | 0.96% |
| Cipla Ltd | 22.64 | 3.82 | 1.08% |
| Torrent Pharmaceuticals Ltd | 59.13 | 14.89 | 0.18% |
SANJIVIN Stock Price Comparison
Compare SANJIVIN with any stock or ETFCompare SANJIVIN with any stock or ETF
SANJIVIN
SANJIVIN Holdings
SANJIVIN Shareholdings
SANJIVIN Promoter Holdings Trend
SANJIVIN Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 1.20%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SANJIVIN Institutional Holdings Trend
SANJIVIN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding History
SANJIVIN Shareholding History
Foreign Institutions
smallcases containing SANJIVIN stock
smallcases containing SANJIVIN stock
Looks like this stock is not in any smallcase yet.
SANJIVIN Events
SANJIVIN Events
SANJIVIN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANJIVIN Dividend Trend
No dividend trend available
SANJIVIN Dividends
SANJIVIN Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSANJIVIN Stock News & Opinions
SANJIVIN Stock News & Opinions
Articles & Videos
Earnings
Sanjivani Paranteral consolidated net profit rises 73.81% in the March 2025 quarter
Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as against Rs 1.26 crore during the previous quarter ended March 2024. Sales rose 41.37% to Rs 18.18 crore in the quarter ended March 2025 as against Rs 12.86 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.12% to Rs 8.09 crore in the year ended March 2025 as against Rs 6.17 crore during the previous year ended March 2024. Sales rose 28.84% to Rs 70.10 crore in the year ended March 2025 as against Rs 54.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales18.1812.86 41 70.1054.41 29 OPM %14.3616.80 -14.7615.14 - PBDT2.842.12 34 10.978.50 29 PBT2.651.88 41 10.357.57 37 NP2.191.26 74 8.096.17 31 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 73.81% in the March 2025 quarter
Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as against Rs 1.26 crore during the previous quarter ended March 2024. Sales rose 41.37% to Rs 18.18 crore in the quarter ended March 2025 as against Rs 12.86 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.28% to Rs 8.10 crore in the year ended March 2025 as against Rs 6.17 crore during the previous year ended March 2024. Sales rose 28.84% to Rs 70.10 crore in the year ended March 2025 as against Rs 54.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales18.1812.86 41 70.1054.41 29 OPM %14.3016.87 -14.7815.14 - PBDT2.832.13 33 10.988.51 29 PBT2.651.89 40 10.367.58 37 NP2.191.26 74 8.106.17 31 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Sanjivani Paranteral recommends final dividend
Sanjivani Paranteral announced that the Board of Directors of the Company at its meeting held on 27 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 5%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sanjivani Paranteral to discuss results
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 15.15% in the December 2024 quarter
Net profit of Sanjivani Paranteral rose 15.15% to Rs 1.90 crore in the quarter ended December 2024 as against Rs 1.65 crore during the previous quarter ended December 2023. Sales rose 15.98% to Rs 17.35 crore in the quarter ended December 2024 as against Rs 14.96 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales17.3514.96 16 OPM %14.7013.17 - PBDT2.672.14 25 PBT2.511.90 32 NP1.901.65 15 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sanjivani Paranteral to discuss results
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 34.50% in the September 2024 quarter
Net profit of Sanjivani Paranteral rose 34.50% to Rs 2.30 crore in the quarter ended September 2024 as against Rs 1.71 crore during the previous quarter ended September 2023. Sales rose 29.50% to Rs 18.13 crore in the quarter ended September 2024 as against Rs 14.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales18.1314.00 30 OPM %15.7715.14 - PBDT3.072.22 38 PBT2.921.99 47 NP2.301.71 35 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Sanjivani Paranteral announces board meeting date
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Sanjivani Paranteral announces board meeting date
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 9 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Sanjivani Paranteral AGM scheduled
Sanjivani Paranteral announced that the 30th Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 33.83%, vs industry avg of 10.1%
Over the last 5 years, market share increased from 0.01% to 0.02%